Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

[1]  L. Crinò,et al.  Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Gnant,et al.  Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer , 2009, BMC Cancer.

[3]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jung-Il Lee,et al.  Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients , 2009, British Journal of Cancer.

[5]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.

[6]  D. Tripathy.  Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study , 2009 .

[7]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer , 2009 .

[8]  V. Heinemann,et al.  Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. , 2008, The oncologist.

[9]  K. Aldape,et al.  Defining prognosis for women with breast cancer and CNS metastases by HER2 status. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Sung Sook Lee,et al.  Brain metastases in breast cancer: prognostic factors and management , 2008, Breast Cancer Research and Treatment.

[12]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[13]  G. Viani,et al.  Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials , 2007, BMC Cancer.

[14]  G. Steger,et al.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer , 2007, Journal of Neuro-Oncology.

[15]  E. Winer,et al.  Brain Metastases: The HER2 Paradigm , 2007, Clinical Cancer Research.

[16]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[17]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[18]  S. Hilsenbeck,et al.  Primary breast cancer phenotypes associated with propensity for central nervous system metastases , 2006, Cancer.

[19]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[20]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  C. Swanton,et al.  Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab , 2006, Acta oncologica.

[22]  E. Winer,et al.  Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Weil,et al.  Breast cancer metastasis to the central nervous system. , 2005, The American journal of pathology.

[24]  D. Kirsch,et al.  Survival after brain metastases from breast cancer in the trastuzumab era. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. André,et al.  Risk factors for brain relapse in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Pinder,et al.  Brain metastases from breast cancer: identification of a high-risk group. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  A. Howell,et al.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.

[29]  G. Hruby,et al.  Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  N. Wigler,et al.  Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. , 2004, European journal of cancer.

[31]  R. Timmerman,et al.  Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[33]  E. Lower,et al.  Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. , 2003, Clinical breast cancer.

[34]  J. Engel,et al.  Determinants and prognoses of locoregional and distant progression in breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[35]  S. Bartelt,et al.  Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  F. Lohr,et al.  Adjuvant treatment of brain metastases. , 2001, Seminars in surgical oncology.

[37]  B. Pestalozzi,et al.  Trastuzumab in CSF. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Dörken,et al.  Brain metastases in breast cancer: prognostic factors and management. , 1999, European journal of cancer.

[39]  R. Sawaya,et al.  Surgical treatment of multiple brain metastases. , 1993, Journal of neurosurgery.

[40]  W. Lane,et al.  Chemotherapy induces regression of brain metastases in breast carcinoma , 1986, Cancer.

[41]  R. Gelber,et al.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. , 1980, International journal of radiation oncology, biology, physics.